Back

Querying functional drivers in primary murine naive and memory T cells using RNP-mediated CRISPR-Cas9 Gene Deletion

Sarkar, S.; Yuzefpolskiy, Y.; Kalia, V.

2026-02-05 immunology
10.64898/2026.02.05.704062 bioRxiv
Show abstract

Cytotoxic CD8 T lymphocytes (CTL) are critical for the clearance of pathogenic cells via antigen-dependent cell lysis, thus providing protection against infectious diseases and cancers. CTLs represent one of the key targets of immunotherapies and vaccine design. While microarray and single-cell RNA sequencing of effector and memory CD8 T cells have identified several promising gene targets that may modulate CD8 T cell responses, their development is slowed down by the financial and time constraints related to the generation of germline knockout mice for further validation studies. Here we present a protocol for conducting efficient deletion of genes from activated effector, as well as resting naive and memory primary murine CD8 T cells using RNP-based Crispr/Cas9 technology. This CRISPR modification of CD8 T cells was then adapted to study the effects of gene deletion in the context of acute memory differentiation as well as chronic exhaustion of CD8 T cells. To this end, we have titrated the necessary dose of antigen-specific CD8 T cells to study their differentiation in acute and chronic infections and confirmed the model by demonstrating rapid expansion of CRISPR mediated PD-1 ablated CD8 T cells in a chronic viral infection. Finally, by combining this methodology with a murine model of subcutaneous tumor challenge, this study provides a unique screening system for genes critical for mediating clearance of malignant tumor cells by CTLs. This study expands current technical capabilities for rapid evaluation of functional role of any candidate gene in CTL responses to infections and cancer through targeted gene deletion at any stage of CD8 T cell differentiation without the need for germline gene deletion mouse models.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Scientific Reports
3102 papers in training set
Top 12%
7.2%
2
Viruses
318 papers in training set
Top 0.7%
6.9%
3
PLOS ONE
4510 papers in training set
Top 25%
6.9%
4
Frontiers in Immunology
586 papers in training set
Top 1%
6.4%
5
PLOS Pathogens
721 papers in training set
Top 2%
6.4%
6
European Journal of Immunology
57 papers in training set
Top 0.1%
4.9%
7
eLife
5422 papers in training set
Top 22%
4.0%
8
The Journal of Immunology
146 papers in training set
Top 0.4%
3.6%
9
iScience
1063 papers in training set
Top 8%
2.6%
10
Cell Reports
1338 papers in training set
Top 22%
1.9%
50% of probability mass above
11
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.5%
1.9%
12
Nucleic Acids Research
1128 papers in training set
Top 10%
1.8%
13
Nature Communications
4913 papers in training set
Top 49%
1.8%
14
ACS Synthetic Biology
256 papers in training set
Top 2%
1.7%
15
Antibody Therapeutics
16 papers in training set
Top 0.2%
1.7%
16
Cell Reports Methods
141 papers in training set
Top 3%
1.5%
17
mSphere
281 papers in training set
Top 4%
1.5%
18
Journal of Immunological Methods
24 papers in training set
Top 0.1%
1.5%
19
PLOS Biology
408 papers in training set
Top 12%
1.3%
20
Immunology & Cell Biology
11 papers in training set
Top 0.1%
1.1%
21
Frontiers in Cellular and Infection Microbiology
98 papers in training set
Top 4%
1.0%
22
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.4%
1.0%
23
mBio
750 papers in training set
Top 10%
1.0%
24
Genome Medicine
154 papers in training set
Top 7%
0.9%
25
Immunology
29 papers in training set
Top 0.8%
0.9%
26
International Journal of Molecular Sciences
453 papers in training set
Top 14%
0.8%
27
Cancer Immunology, Immunotherapy
11 papers in training set
Top 0.3%
0.8%
28
Frontiers in Pharmacology
100 papers in training set
Top 5%
0.8%
29
npj Vaccines
62 papers in training set
Top 0.5%
0.7%
30
Science Advances
1098 papers in training set
Top 31%
0.7%